B. longum

1. What conditions has B. longum been studied for?

• Chronic constipation in older adults (B. longum BB536; randomized, double-blind, placebo-controlled trial in elderly individuals).

• Ulcerative colitis / colitis models (B. longum NSP001-derived extracellular vesicles studied in mice; “postbiotic” concept).

• Acetaminophen (APAP)-induced acute liver injury (B. longum R0175 studied in mice).

• Antibiotic-associated pediatric asthma risk (early life) (observational cohort linking breastfeeding-associated enrichment of B. longum subsp. infantis with reduced asthma odds after antibiotics).

• Viral gastroenteritis in children (including rotavirus) (clinical trial used a multi-strain probiotic mixture including B. longum; in vitro rotavirus inhibition testing of isolates).

• Central nervous system (CNS) outcomes (a systematic review of probiotic RCTs in animals/humans is referenced, but the provided excerpt does not specify B. longum-specific CNS indications or results).

• Parkinson’s disease medication interactions (mechanistic work showing some Bifidobacterium species including B. longum can metabolize L-DOPA in vitro; clinical cohort correlations between Bifidobacterium abundance and L-DOPA dose/tyrosine levels).

• General gastrointestinal disorders and infections (review-level claims that Bifidobacterium species including B. longum are used to prevent/treat GI disorders, including infections and cancers; these are broad statements without specific trial details in the abstracts provided).

2. Does it work in treating those conditions? Summarize the evidence.

• Chronic constipation (elderly): mixed/partial evidence. In a 4-week randomized, double-blind, placebo-controlled trial (B. longum BB536, 5 × 10¹⁰ CFU daily), the primary endpoint (between-group difference in change in total Constipation Scoring System score at week 4) was not statistically significant (P = 0.074). However, the BB536 group improved from baseline (P < 0.01), and there was a significant between-group difference in stool frequency (P = 0.008) and a trend for “failure of evacuation” (P = 0.051). This supports a modest benefit on bowel movement-related outcomes, but not definitive improvement on the prespecified primary endpoint.

• Ulcerative colitis/colitis: promising preclinical evidence (not yet clinical). In mice, extracellular vesicles from B. longum NSP001 (NEVs) alleviated colitis by improving intestinal barrier function, modulating immune cell differentiation, promoting short-chain fatty acid (SCFA) production, and suppressing the STAT3 pathway. Effects were also seen in pseudo-germ-free mice, suggesting benefit not solely dependent on reshaping the microbiota. This is mechanistic animal evidence; it does not establish efficacy in humans.

• Acetaminophen-induced liver injury: promising preclinical evidence (not yet clinical). In mice, B. longum R0175 reduced liver injury markers by diminishing inflammation, oxidative stress, and hepatocyte death, and improved dysbiosis. Mechanistically, benefits were linked to Nrf2 pathway activation; an Nrf2 inhibitor (ML385) counteracted effects. The study also identified sedanolide (a microbiota-derived intestinal metabolite) as a key Nrf2 agonist associated with protection. This is strong mechanistic animal evidence but not proof of human clinical benefit.

• Antibiotic-associated asthma risk in children: associative evidence (not a treatment trial). In the CHILD cohort, children who received antibiotics without breastfeeding had ~3-fold higher asthma odds, while this association was not seen in children who received antibiotics with breastfeeding. Protection was linked to microbiome “re-balancing” and enriched colonization with B. longum subsp. infantis, associated with specific fucosylated human milk oligosaccharides (HMOs). This supports a potential protective role of B. infantis enrichment in early life, but it is not a randomized supplementation trial of B. longum.

• Viral gastroenteritis (children): limited attribution to B. longum alone. A double-blind trial in 29 pediatric patients used a six-strain mixture including B. longum given twice daily for 1 week; the abstract states probiotics significantly shortened duration of illness (text truncated), and in vitro testing found a B. longum isolate had the greatest inhibitory effect on rotavirus. Because the clinical intervention was multi-strain, the specific contribution of B. longum cannot be isolated from this abstract alone.

• Parkinson’s disease / L-DOPA handling: evidence suggests a potential drug–microbe interaction rather than a therapeutic benefit. Clinical cohort data showed Bifidobacterium abundance correlated positively with L-DOPA dose and negatively with serum tyrosine. In vitro, certain species including B. longum metabolized L-DOPA to DHPLA (especially upregulated in nutrient-limited conditions). This suggests B. longum could potentially affect drug availability, but the clinical impact on symptom control is not established in the abstract.

3. What health benefits does it have?

• Supports bowel function (constipation-related outcomes). In elderly adults with chronic constipation, B. longum BB536 improved bowel movement-related measures, including a significant between-group improvement in stool frequency (P = 0.008), despite not meeting the primary endpoint for total constipation score.

• Anti-inflammatory and barrier-supporting potential in colitis models. B. longum NSP001-derived extracellular vesicles improved intestinal barrier function, modulated immune differentiation, increased SCFAs, and suppressed STAT3 signaling in mouse colitis models.

• Potential antioxidant/cytoprotective effects via Nrf2 signaling (preclinical). In APAP-challenged mice, B. longum R0175 activated the Nrf2 pathway, reduced oxidative stress and inflammation, and reduced hepatocyte death; a candidate mediator was the microbiota-derived metabolite sedanolide.

• Early-life microbiome benefits (context-dependent). In an infant cohort, enrichment of B. longum subsp. infantis (associated with breastfeeding and specific fucosylated HMOs) was linked to functional microbiome changes associated with reduced antibiotic-associated asthma risk.

• Potential antiviral activity (strain-specific; limited clinical specificity). A B. longum isolate showed strong in vitro inhibition of rotavirus in a plaque reduction assay, and a multi-strain probiotic including B. longum shortened illness duration in pediatric viral gastroenteritis (exact endpoint text truncated).

• General probiotic-associated metabolic contributions (review-level). Reviews in the abstracts associate bifidobacteria (including B. longum) with production of potentially beneficial metabolites such as short-chain fatty acids, conjugated linoleic acid, and bacteriocins, though these are broad claims not tied to a specific B. longum clinical outcome in the provided text.

4. Does it have any downsides or side effects?

• Generally well tolerated in the cited human RCT. In the elderly constipation trial of B. longum BB536 (5 × 10¹⁰ CFU daily for up to 4 weeks), the authors reported few adverse events related to the probiotics.

• Potential medication interaction risk (mechanistic concern). In vitro, B. longum (among other Bifidobacterium species) metabolized L-DOPA to DHPLA, and clinical cohort data linked higher Bifidobacterium abundance with higher L-DOPA dose. This raises a plausible downside: certain gut Bifidobacteria might contribute to peripheral drug metabolism under some conditions. The abstract does not prove harm or quantify clinical impact, but it suggests a mechanism that could matter for Parkinson’s medication management.

• General probiotic safety caveat (not specific to B. longum in the provided text). One abstract notes that some lactic acid bacteria can produce toxic substances or show virulence traits and references FAO/WHO guidance for safety characterization (e.g., antibiotic resistance, toxin production, hemolysis, infectivity in immunocompromised hosts). The excerpt does not provide B. longum-specific safety problems, but it underscores the importance of strain-level safety assessment.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

• No direct human pharmacogenomic (host genetic variant) findings are provided in these abstracts. None of the included abstracts report outcomes stratified by human genotype or specific gene variants that modify response to B. longum supplementation.

• Mechanism-linked considerations (not pharmacogenomics per se):

  • Nrf2 pathway dependence (preclinical): In mice, protection from APAP liver injury by B. longum R0175 depended on Nrf2 signaling (blocked by an Nrf2 inhibitor). This suggests that host variation affecting Nrf2 pathway function could hypothetically influence response, but no genetic data are presented.

  • Drug metabolism by microbes (Parkinson’s/L-DOPA): B. longum can metabolize L-DOPA in vitro. This is a microbiome-driven pharmacology interaction rather than a host-genotype interaction, but it could still affect drug exposure in some patients.

  • HMO-driven colonization (infants): Breast milk fucosylated HMOs were associated with B. infantis enrichment and asthma-protective functional microbiome changes. The abstract does not discuss maternal genetics (e.g., FUT2 secretor status), but it implies that differences in milk oligosaccharide profiles may influence B. longum subsp. infantis colonization and downstream effects.

References

1. Gut Bifidobacteria Populations in Human Health and Aging.
   Silvia Arboleya, Claire Watkins, Catherine Stanton, R Paul Ross (2016) - Frontiers in microbiology
2. Recent Development of ProbioticBifidobacteriafor Treating Human Diseases
   Jun Chen, Xinyi Chen, Chun Loong Ho (2021)
3. Effect of Probiotics on Central Nervous System Functions in Animals and Humans: A Systematic Review.
   Huiying Wang, In-Seon Lee, Christoph Braun, Paul Enck (2016) - Journal of neurogastroenterology and motility
4. Efficacy of
   Susan Mills, Bo Yang, Graeme J Smith, Catherine Stanton, R Paul Ross (2023) - Gut microbes
5. Breastfeeding enrichment of B. longum subsp. infantis mitigates the effect of antibiotics on the microbiota and childhood asthma risk.
   Darlene L Y Dai, Charisse Petersen, Courtney Hoskinson, Kate L Del Bel, Allan B Becker, Theo J Moraes, Piushkumar J Mandhane, B Brett Finlay, Elinor Simons, Anita L Kozyrskyj, David M Patrick, Padmaja Subbarao, Lars Bode, Meghan B Azad, Stuart E Turvey (2023) - Med (New York, N.Y.)
6. Usefulness of Bifidobacterium longum BB536 in Elderly Individuals With Chronic Constipation: A Randomized Controlled Trial.
   Tsutomu Takeda, Daisuke Asaoka, Shuko Nojiri, Naotake Yanagisawa, Yuji Nishizaki, Taro Osada, Shigeo Koido, Akihito Nagahara, Noriko Katsumata, Toshitaka Odamaki, Jin-Zhong Xiao, Toshifumi Ohkusa, Nobuhiro Sato (2023) - The American journal of gastroenterology
7. Bifidobacterium longum NSP001-derived extracellular vesicles ameliorate ulcerative colitis by modulating T cell responses in gut microbiota-(in)dependent manners.
   Xinke Nie, Qiqiong Li, Haihua Ji, Shanshan Zhang, Yuchen Wang, Junhua Xie, Shaoping Nie (2025) - NPJ biofilms and microbiomes
8. The gut core microbial species Bifidobacterium longum: Colonization, mechanisms, and health benefits.
   Yue Xiao, Lijuan Huang, Jianxin Zhao, Wei Chen, Wenwei Lu (2025) - Microbiological research
9. Bifidobacterium longum R0175 protects mice against APAP-induced liver injury by modulating the Nrf2 pathway.
   Shengjie Li, Aoxiang Zhuge, Jiafeng Xia, Shuting Wang, Longxian Lv, Kaicen Wang, Huiyong Jiang, Ren Yan, Liya Yang, Xiaoyuan Bian, Xianwan Jiang, Qiangqiang Wang, Shengyi Han, Lanjuan Li (2023) - Free radical biology & medicine
10. Safety Evaluations of
    Min Jeong Kim, Seockmo Ku, Sun Young Kim, Hyun Ha Lee, Hui Jin, Sini Kang, Rui Li, Tony V Johnston, Myeong Soo Park, Geun Eog Ji (2018) - International journal of molecular sciences
11. Effect of
    Marco Toscano, Roberta De Grandi, Laura Stronati, Elena De Vecchi, Lorenzo Drago (2017) - World journal of gastroenterology
12. A novel pathway of levodopa metabolism by commensal Bifidobacteria.
    M S Cirstea, A Creus-Cuadros, C Lo, A C Yu, A Serapio-Palacios, S Neilson, S Appel-Cresswell, B B Finlay (2023) - Scientific reports
13. Effects of Human Milk Oligosaccharides in Infant Health Based on Gut Microbiota Alteration.
    Miaomiao Hu, Mengli Li, Chenchen Li, Ming Miao, Tao Zhang (2023) - Journal of agricultural and food chemistry
14. Probiotic bacteria, B. longum and L. acidophilus inhibit infection by rotavirus in vitro and decrease the duration of diarrhea in pediatric patients.
    Do Kyung Lee, Jae Eun Park, Min Ji Kim, Jae Goo Seo, Ji Hyuk Lee, Nam Joo Ha (2015) - Clinics and research in hepatology and gastroenterology
15. Yacon flour and Bifidobacterium longum modulate bone health in rats.
    Fabiana Carvalho Rodrigues, Adriano Simões Barbosa Castro, Vívian Carolina Rodrigues, Sérgio Antônio Fernandes, Edimar Aparecida Filomeno Fontes, Tânia Toledo de Oliveira, Hércia Stampini Duarte Martino, Célia Lúcia de Luces Fortes Ferreira (2012) - Journal of medicinal food
16. Bifidobacterium longum subsp. longum BG-L47 boosts growth and activity of Limosilactobacillus reuteri DSM 17938 and its extracellular membrane vesicles.
    Ludwig Ermann Lundberg, Punya Pallabi Mishra, Peidi Liu, Manuel Mata Forsberg, Eva Sverremark-Ekström, Gianfranco Grompone, Sebastian Håkansson, Caroline Linninge, Stefan Roos (2024) - Applied and environmental microbiology
17. Bifidobacterium longum subsp. longum 5
    Mônica F Quintanilha, Vivian C Miranda, Ramon O Souza, Bruno Gallotti, Clênio Cruz, Elandia A Santos, Jacqueline I Alvarez-Leite, Luís C L Jesus, Vasco Azevedo, Luísa M Trindade, Valbert N Cardoso, Enio Ferreira, Bárbara A Carvalho, Pedro M G Soares, Angélica T Vieira, Jacques R Nicoli, Flaviano S Martins (2022) - Life sciences
18. A Systematic Review on the Effects of Different Types of Probiotics in Animal Alzheimer's Disease Studies.
    Tanja J de Rijke, M H Edwina Doting, Saskia van Hemert, Peter P De Deyn, Barbara C van Munster, Hermie J M Harmsen, Iris E C Sommer (2022) - Frontiers in psychiatry
19. Identification of a prototype human gut
    Giulia Alessandri, Federico Fontana, Chiara Tarracchini, Sonia Mirjam Rizzo, Massimiliano G Bianchi, Giuseppe Taurino, Martina Chiu, Gabriele Andrea Lugli, Leonardo Mancabelli, Chiara Argentini, Giulia Longhi, Rosaria Anzalone, Alice Viappiani, Christian Milani, Francesca Turroni, Ovidio Bussolati, Douwe van Sinderen, Marco Ventura (2023) - Frontiers in microbiology
20. Selenium-enriched Bifidobacterium longum DD98 attenuates irinotecan-induced intestinal and hepatic toxicity in vitro and in vivo.
    Hui Zhu, Chunyi Lu, Fei Gao, Zhixiang Qian, Yu Yin, Shidong Kan, Daijie Chen (2021) - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie